

-

3.1.4. –

:

,

.....	4
1.	-
-	-
.....	10
1.1. -	.
.....	10
1.2. .	-
-
1.3.	18
-	-
.....	20
1.4.	24
.	24
2.	33
2.1.	33
2.2.	37
2.3.	38
.....	38
2.4.	40
2.5.	42
2.6. ,	-
.....	43
2.7.	50
3. -	-
.....	51
3.1. -
	51

3.2.	-	-
	54
3.3.		
	-
		69
4.		
	78
4.1.	-	-
	
		78
4.2.		-
	80
4.3.		-
	
		83
4.4.		,
	
		90
4.5.		,
	
		91
4.6.	-	-
	
		100
	104
	119
	120
	121
	123

,
 ,
 26–32 % [27].
 ,
 . [28; 60; 74].
 ,
 [61; 65].
 ,
 20 .
 1%
 - 4 [12; 75].
 2,

rs1800470)

(SERPINE-1 5G (-675)4G)

4.

3-

- 1 (TGF- (rs1800470))

eNOS3 (G894T).

(12 ,

Streptococcus agalactiae)

NOS3 G894T, TGF- (rs1800470))

1.

Streptococcus agalactiae

2.

3.

- 1 (TGF- (rs1800470)),

- eNOS3 (G894T) -

: 3 -

4. - -

.

.

« » . -

,

,

« » .

4 , 3

,

.

« -2019»

(. - , 2019); - -

« » (. , 2020); III

» , -

» (. - , 2021).

« - »

« , , -

»

« » (

25.11.2022 4).

.

,

.

,

, -

.

(-

), -

, -

.

•

3.1.4 – « -

».

, 1, 4 5 -

« ». -

• 136 -

, , , -

, 2 -

, , , ,

, 125 ,

78 .

15 10 47 .

1

-

1.1.

-

.

.

.

,

-

10

2005 . 2 : 2005 . – 250,8 . (17,9

100), 2016 . – 516,1 . (28,0 100). -

,

25–30%

-

-

[64; 75; 85].

15,8–49,8% , 30–32,8% – , 18,3–36,7% – ,

32,2% – , 40,0% – , 31,2% – , 45,0% – , 44,2–

59,6% – , 34,1% – [71; 73; 81; 83].

10 15%

.

,

54 , , -

.

3,2

-

50%

-

. ,

6,2

2,32

[39; 116].

7,5% 2011 . 12,3%

2013 . [53; 78].

15–43%.

[1; 61; 87].

6,0%,

[7; 9; 15].

[95; 109; 114].

[20].

[22].

(

, , , .), , ,
 . , -
 , - , .
 - : , -
 , , , .
 [11; 84; 108].

45-83 100 . . , 26
 . , - 32%, -
 - 29%, - 15%, -
 - 8%, - 6%, - 2%.
 15 - 75% - -
 [3; 65; 94].

. ., 2020 ., [60], , -
 , , -
 . : -
 , -
 , , -
 [10; 13; 18; 91].

, - , 30-70% [30; 36].
 e e e -
 a e o ,
 27% .
 150 . [31; 102].

– [67].

[89; 104].

[21; 97].

[40; 107].

0,5–2% [77].

[92].

11–58% [41; 54; 74].

5%,

55%.

75–89%

[6; 17; 36; 74].

... (2020) [39], -

5-10 , . -

[74]. -

.

, -

(,)

-),

.

[40; 120]. -

, , -

, , [49; 79].

-

, 1,5 2,3 . -

2 ,

66% .

, -

. , -

1000 [14]. -

, -

[86].

,

-

[19].

[57; 98].

10–50%

5

80% [35; 50; 82].

150

[115].

[5; 58].

[66; 93].

()

45; 124].

1985

I — ;

II — ;

III — , 15 6 ;

IV — ;

V — 15 6 .

I II —

III (48–72)

, , , -
 , . -
 , (, .), -
 . -
 : ,
 , , -
 . (, .),
 (, , .).
 , - ,
 , -
 . , -
 150 400 . -
 , -
 , -
 (, , .), -
 [27; 59].

, , ,
 , [65]. -
 . -
 , , .
 . . , -
 , -
 . -
 , -

[48; 69; 70; 74].

[60].

1.2.

SERPINE1

- 675

5G 4G.

5G

, 4G -

[110].

4

(4G/4G)

-1

[112].

(NOS C774T)

[108].

1 (TGF 1),

TGF .

. *TGF 1*

-509

TGF 1

. [121; 122].

(TGF-)

;

;

1.3.

[43; 119].

Cochrane

18

[117].

[12].

. . (2016)

[29; 42].

Cochrane

[68; 113].

B,

[88].

2014 .

» : , -
 , , , , -
 [76; 116].

(0,25%), . -
 () . -
 , ,) . -
 , , . , -
 , -
 [52; 90].

. , -
 [25].

0,5% , -
 . -
 [111].

, , -
 . , -
 , -
 [125].

, - , -
 . -
 () () -

[106].

[56; 74].

[123].

[24].

, , ,
 . - . -
 , , -
 ,
 [33].

1.4.

, -
 -
 , , -
 . -
 , -
 , -
 , [51].
 . 1876 -
 . -
 , -
 . Elfstrom Grafstrom (, 1898) -
 , -
 . , 1905 ., , -
 -

，
 . . . - , 1934 ., «
 », ,
 [32].

40-
 ,
 .
 ,
 .

70- . XX
 80-
 . 40
 .
 -
 ,
 .
 :

() -
 [100].

50×10⁹/
 350×10⁹/ (- 200×10⁹/).

,
 ,
 ,
 ,

[46; 63].

TGFb

[96].

[46].

[16].

«PlasmoliftingTM» –

— ,
[101].

[2].

VEGF,

[8].

50,0%

() [81].

:

, . , -
, -

[38; 105].

-

.

,

DGF

-

.

PDGF

,

.

,

,

,

.

-

PDGF

[46].

,

7

-

.

.

,

,

-

.

,

.

-

.

:

-

,

,

,

,

[4; 72].

-

.

.

-

[46].

.

,

,

/

-

[23].

,

-

-

,

,

,

.

.

2.1.

-

-

:

-

· , 1023

-

1130- 20.10.2020 . «

« ».

-

(

17.12.2019 (11)).

862

· 2019

2021 .

-

-

·

-

:

- 18-49 ;

- (37-42);

- ;
 - 12 ;
 2- -
 : -
 , 3 , -
Streptococcus agalactiae.

- :
 - ;
 - , -
 ;
 - ($100 \cdot 10^9 /$);
 - ($90 /$);
 - ;
 - 3 ;
 - , ;
 - ;
 - , , ;
 - ;
 - -

.
 ,
 (81)
 2- . 40 (1-), -
 (). (2-) 41
 ,
 () -
 I (-
 1,0) 30 -
 1.

I

– 862 ()
1130- 20.10.2020 .



(n=81)



(n=781)

II

– 81 ()
1130- 20.10.2020 .



(1-) – n=40,



(2-) – n=41,

*NOS3 G894T, TGF- (rs1800470),
SERPINE-1 5G (-675)4G*

6 (3-, 5-, 8-)

-

38

910,

(90%) L-

(10 %),

.

2.3.

10

19G

30

«Plasmo-

lifting ».

900 / 5 .

3000 / 5 ,

, — ,

» ,

(2).

6,0–9,0 .

(23G, SFM


Hospitalproducts GMBH, , 3).

3–5

,

.

(3).



2 -



3.

1-

).

, 1,5-2,0

()

5

, 2,5

7,0-8,0 (4).

5-10 .

2.4.

,
 () :
 , , , (-
 , ,) ((-
)) ().
 - , , -
 (), (), ,
 , , (), , pH , ,
 , .
 :
 (), (), -
 (), ().
 -
 «CR-10» «Amelung» (), «Automatic Analyzer 912»
 «Automatic Analyzer 902» «Hitachi» (), «EsysLyte AVL-9180»
 «AVL» (), «SYSMEX KX-21N» «Roch» (-)).
 -
 -
 .
 81 , -
 .
 -
 :

Laura-Lee Boodram.

1,5 Eppendorf 700
700 -
1 (10 - HCL 1), -
8000 /5 ,
(2-3).
300 2 (20 -
- HCL 10 - , - 7,4) ,
10%
SDS 25 10 -
30 60 -
1 .
250 5,3 -NaCl , -
10000 / 5 . -
700 -
11000 / 2 . -
70% - 1 , -
13000 / 1,5 . , -
- . -
100 0,1 - -
HCl, 8,5. , 65
5 .

Real-Time PCR.

CFX96 Touch™ Real-Time PCR Detection System

().

« -
 », -
 (Voluson 8, Toshiba Xario ssa-660a) 3-, 5- 8- -
 . -
 , , , - ,
 , . 6 -
 ,

2.6. ,

18 (- 18 , - 21 ,
 =0,33), - 49 (- 49 , -
 - 48). , -
 28,0 (26,0; 34,0) (- 29,0 (25,0; 33,0) , -
 - 30,0 (26,0; 34,0) , =0,14).
 ,
 151 ,
 157 - .
 178 182 .
 167,0 (159,0; 171,0) -
 164,0 (160,0; 170,0) ,
 =0,12. , -
 , 144,0 ,

159,0 .

, 82,0 (75,0; 96,0) ,

87,0 (77,0; 94,0) , =0,24.

,

.

,

-

-

,

-

,

,

,

-

, 155,0 (17,9%), 157,0 (18,2%), 146,0 (16,9%), 42,0 (4,8%),

67,0 (7,7%) .

13,0 (16,0%), 21,0 (25,9%), 11,0 (13,6%), 5,0 (6,2%),

7,0 (8,6%) (1).

,

,

,

,

,

12,0 (11,0; 13,0) ,

-

12,0 (12,0;

13,0) , =0,18.

- 28,0

(27,0; 30,0) 28,0 (28,0; 32,0)

, =0,08,

4,0 (3,0; 5,0) 5,0 (4,0;

5,0) , p=0,24.

,

-

362,0 (42,0%) 30,0 (37,0%) -

, =0,54),

x 232,0 (26,9%) 23,0 (28,4%)

, =0,46,

x x - 268,0 (31,1%) 28,0 (34,6%) -

, =0,11.

			4
	(n=862)	(n=81)	
1	2	3	4
,	29,0 (25,0; 33,0)	30,0 (26,0; 34,0)	0,14
/ ² ,	28,4 (24,6; 32,2)	29,6 (26,3; 31,4)	0,10
,	82,0 (75,0; 96,0)	87,0 (77,0; 94,0)	0,24
,	167,0 (159,0; 171,0)	164,0 (160,0; 170,0)	0,12
-	155,0 (17,9%)	13,0 (16,0%)	0,62
-	157,0 (18,2%)	21,0 (25,9%)	0,03*
-	146,0 (16,9%)	11,0 (13,6%)	0,09
	42,0 (4,8%)	5,0 (6,2%)	0,48
	67,0 (7,7%)	7,0 (8,6%)	0,66
,	12,0 (11,0; 13,0)	12,0 (12,0; 13,0)	0,18
,	28,0 (27,0; 30,0)	28,0 (28,0; 32,0)	0,08
- ,	4,0 (3,0; 5,0)	5,0 (4,0; 5,0)	0,24
	362,0 (42,0%)	30,0 (37,0%)	0,54
	232,0 (26,9%)	23,0 (28,4%)	0,46
	268,0 (31,1%)	28,0 (34,6%)	0,11

1			
1	2	3	4
1-	2,0 (2,0; 4,0)	2,0 (2,0; 3,0)	0,38
1-	2,0 (1,0; 3,0)	2,0 (1,0; 2,0)	0,26
	171,0 (19,8%)	23,0 (28,4%)	0,04*
I	122,0 (14,2%)	18 (22,2%)	0,02*
-	26 (3,0%)	3 (3,7%)	0,16
	4 (0,5%)	1 (1,2%)	0,01*
	202 (23,4%)	11 (13,6%)	<0,01**
-	194 (22,5%)	14 (17,3%)	0,04*
-	72 (8,4%)	12 (14,8%)	0,01*
	49 (5,7%)	6 (7,4%)	0,22
,	190 (22,0%)	28 (34,6%)	<0,01**
-	76 (8,8%)	7 (8,6%)	0,36
	36 (4,2%)	5 (6,2%)	0,08
	44 (5,1%)	9 (11,1%)	<0,01**

* – <0,05; ** – p<0,01.

2,0 (1,0; 3,0) -

2,0 (1,0; 2,0) -

	, .)	344 (39,9%)		(-
14 (17,3%)			.		-
	, , .)		262 (30,4%)	24 (29,6%)	-
	.		,	,	-
			,		-
	.	I			-
202 (23,4%)					-
11 (13,6%)			.		-
			-	194 (22,5%)	-
				14 (17,3%)	-
	.	-		II	-
			72 (8,4%)		,
12 (14,8%)			.		-
		III		,	-
	,		190 (22,0%)	,	-
				28 (34,6%)	-
	.		,	,	-
	,		,		-
			49 (5,7%), 36 (4,2%), 76 (8,8%), 44 (5,1%)		-
			,	6 (7,4%),	-
5 (6,2%), 8 (9,8%), 9 (11,1%) –			(1).	-
			,		-
3,0 (2,0; 6,0)					-
			2,0 (2,0; 4,0)		-
	.				-
	,				-
(50,9%)	,				-
					439

2.7.

					-
				«Microsoft Excel», «Statistica 10.0», «Eviews 9.0».	-
					-
				«Statistica 10.0».	-
		25	75	(Q25; Q75).	-
	(<0,05)			(<0,001)	-
	()			()	-
				-	-
	95%			U	-
				-	-
					-
				<0,05	-
	, <0,01 –			, <0,001 –	-
					-
				(-
)				-
		ROC-		ROC-	-
					-
					-

3

-

-

-

.

-

3.1.

-

-

-

,

-

81

,

9,4%,

()

()

-

42

,

4,8%.

-

27

(3,1%).

12

-


,

,

(1,4%).


-

4.



4 - -

3- 29 81
 (35,8%), 4-5- - 21 81 (25,9%) -
 , 6- - 31 (38,3%).
 46 (56,8%) 81 -
 ,
 26 (32,0%), 9
 (11,1%). 13 81
 (16,0%), - 16 (19,7%) - 5.



5 –

-

, :
 (24 81 (29,6%)), « »
 (62 81 (76,5%).
 .
 ,
 – 28 (34,6%),
 12 (14,8%),
 16 (19,8%),
 – 10 (12,3%)
 .
 -
 .
 scherichia

54
coli (18 (22,2%)), 14
Staphylococcus epidermidis 16 (19,8%), 7
(43,7%). *Enterococcus faecalis*
17 (21,0%), 9
(52,9%). *Enterococcus faecium* – 16
(19,8%), 6
(37,5%).

,
(12 81 (14,8%)).
,
,
.
(7- 12 (58,3%)) - ,
3- -
(25,0%), 2- -
(16,7%).

3.2.


-
-
- ,
,
,
,
,
(2).

	(n=81)	(n=781)	
,	12,0 (12,0; 13,0)	12,0 (11,0; 14,0)	0,225
,	28,0 (27,0; 30,0)	28,0 (28,0; 31,0)	0,348
,	4,0 (4,0; 5,0)	5,0 (4,0; 5,0)	0,471
, . .,%	26,0 (32,1%)	336,0 (43,0%)	0,042*
, . .,%	38,0 (46,9%)	194,0 (24,8%)	<0,001***
, . .,%	17,0 (21,0%)	251,0 (32,1%)	0,018*
	4,0 (3,0; 5,0)	2,0 (2,0; 3,0)	0,012*
1	3,0 (2,0; 3,0)	1,0 (1,0; 2,0)	<0,001***

* – $p < 0,05$; ** – $p < 0,01$, *** – $p < 0,001$.

, -
 , -
 , -
 4,0 (3,0; 5,0), - 3,0 (2,0; 3,0). , -
 2,0 (2,0; 3,0)
 1,0 (1,0; 2,0) , 2

				- 24
(29,6%),		- 16 (19,8%),		
	(15	81 (18,5%)),	9	-
(11,1%),		5 (6,2%).		
,		,		-
			- 129	
(16,5%),	- 62	(7,9%),		-
	146	(18,7%),		
33	(4,2%),		- 131	
	(16,8%).			-
		6.		-
		,		-
	(=0,002	=0,015)	-
		,		-
	5	(6,1%),	38	
	(4,8%),	(=0,089).		
				-
			7	-
(8,6%),		- 12	(14,8%).	
				42
(5,4%),		54	(6,9%).	-
				-
,				.



6 –

, ,

14,6 (9,5; 18,2)

, 12,2 (9,7; 16,0) , =0,036.

« », 2020 . -

, 3. -

, -

55 81 (67,9%), , -

289 781 (37,0%), -

, <0,001. , -


, -

3 –


	(/ ²)	()	(/) 2-3-
	<18,5	12,5-18,0	0,44-0,58
	18,5-24,9	11,5-16,0	0,35-0,50
	25,0-29,9	7,0-11,0	0,23-0,33
	30,0	5,0-9,0	0,17-0,27

(46 (56,8%) 358
 (45,8%)), =0,037.
 16 (19,7%) 148
 (17,0%), =0,488. « » 12
 (14,8%) 48
 (5,5%), =0,003. , -
 , -
 .
 -
 , 8 (9,8%),

4	(4,9%), 4	(4,9%)			21
	(2,6%), 16	(2,0%), 29	(3,7%)		.
			(<0,001)	(=0,04),	-
5	(6,1%)	24	(3,1%)		,
=0,044.					-
		1			-
		- 22	(27,2%),	180	(23,0%)
		, =0,128.			-
20		(24,7%)	174	(22,3%)	,
=0,544.	-				9
	(11,1%),				
5	(6,2%),			- 2	(2,5%),
2	(2,5%)				
.					-
	63	(8,1%),			,
		(=0,033).			
				- 33	
(4,2%),			12	(1,5%).	
,			, 3-		-
	18		(22,2%),	172	
(22,0%), =0,845.					6
		(7,4%),	43		(5,5%),
=0,056.			5	(6,2%)	
31	(4,0%)		, =0,068.	«	-
	»		9	(11,1%),	-
				67	
(8,6%), =0,064.					-
	10	(12,3%)	,	37	



7 –




8 –

(5,6%), =0,115, - 1 (1,2%)
 46 (5,9%), =0,083 (-
 4).
 4 -

	(n=81)	(n=781)	
, . ., (%)	62 (76,5%)	377 (48,2%)	<0,001***
	33 (40,7%)	169 (21,6%)	<0,001***
	15 (18,5%)	71 (9,1%)	<0,001***
	10 (12,3%)	63 (8,1%)	0,171
	1 (1,2%)	58 (7,4%)	0,457
	3 (3,7%)	11 (3,2%)	0,256
	0 (0%)	5 (0,6%)	0,366
, . ., (%)	19 (23,5%)	404 (51,8%)	<0,001***
1-	2 (2,5%)	200 (25,6%)	<0,001***
, . ., (%)	3 (3,7%)	59 (7,6%)	0,214
	5 (6,2%)	55 (7,0%)	0,801
	8 (9,8%)	44 (5,6%)	0,115
	1 (1,2%)	46 (5,9%)	0,083

* - <0,05; ** - p<0,01, *** - p<0,001.

,
 (<0,001),
 (<0,001).
 , (<0,001).
 1
 , , (<0,001).
 : 6 7 (8,6%), 6 12
 22 (27,2%), 12 33 (40,7%). -
 - 181 (23,2%), 6 12 - 122 (15,6%),
 12 - 74 (9,5%). 6
 (<0,001), 6 12 -
 (p=0,006),
 12
 (<0,001). 9.



9 –

2,67 (=2,67, 95% 1,6-4,2).

(=2,83, 95% 1,7-3,9).

(=1,83, 95% 1,1-3,2).

(=3,6, 95% 1,9-6,7).

(=1,55, 95% 1,0-3,0).

95% 1,3-5,2).

(=2,66,

(=1,42, 95% 1,1-2,9).

(=2,83, 95% 1,2-5,5).

(=2,57, 95% 1,3-5,1).

, *Escherichia coli* (=2,77, 95% 1,2-5,6), *Enterococcus faecalis* (=2,48, 95% 1,2-4,9) *Streptococcus agalactiae* (=4,3, 95% 2,1-8,9)

(=3,5, 95% 1,6-7,1).

(=2,49, 95% 1,2-5,0)

(=2,27, 95% 1,1-4,7) -

-

.

,

,

-

-

.

6 12

(=1,15, 95% 1,0-2,2).

12

(=4,66, 95% 2,3-9,4).

5.

5 -

-

-

-

(

-

)

		95%	
1	2	3	4
	2,67	1,6-4,2	<0,001***
	2,83	1,7-3,9	0,002**
	1,83	1,1-3,2	0,015*
	3,6	1,9-6,7	<0,001***
	1,55	1,0-3,0	0,037*
	2,66	1,3-5,2	0,003**
-	1,42	1,1-2,9	0,033*

5			
1	2	3	4
	2,83	1,2-5,5	0,003**
<i>Escherichia coli</i>	2,77	1,2-5,6	<0,001***
<i>Enterococcus faecalis</i>	2,48	1,2-4,9	0,020*
<i>Streptococcus agalactiae</i>	4,3	2,1-8,9	<0,001***
	3,5	1,6-7,1	<0,001***
	2,49	1,2-2,5	<0,001***
	2,27	1,1-4,7	<0,001***
6 12	1,15	1,0-2,2	0,006**
12	4,66	2,3-9,4	<0,001***

* – <0,05; ** – p<0,01, *** – p<0,001.


-
 - 29 (35,8%)
 123 (15,7%), <0,001.
 ()
 1,2% (1), - 0,7% (6), =0,657.
 , , 7 -
 (8,6%), 28 (3,5%), =0,028. -
 -
 () -
 .
 -
 : (16 81 (19,7%), -
 (5 (6,2%)), (2 -
 (2,5%)). ,
 .
 122 (15,6%), - 28 -
 (3,6%). 8 ,
 1,0%. (=0,334), -
 (=0,248) (=0,248) -
 .
 , -
 . 1- 16 -
 (19,7%), 2- - 10 (12,3%), 3- - 7 -
 (8,6%). : -
 1- 96 (12,3%), 2- -
 49 (6,3%), 3- - 22 (2,8%). -
 1- -

(=0,057), 2-
(=0,039), 3- (=0,006).

30 (37,0%) 256
(32,8%), =0,439. ()
18 (22,2%), 88
(11,2%),
11 (13,5%) 36 – (4,6%), ,
, (=0,004)
(<0,001).

-
. (15
– 18,5%), (13 – 16,0%), -
(10 – 12,3%), (8 -
9,8%). , ,
: (122 – 15,6%),
(80 – 10,2%), (48
(6,1%)), (48 (6,1%)). -
-
, -
(=0,497), (=0,109),
(=0,195),
(=0,034).

-
(25 (30,8%) 215
(27,5%)), =0,488; (3 (3,7%),
19 (2,4%)), =0,215.



, (1985 .) .
 I -
 5 (6,2%), II - 4 (4,9%), III - 17
 (20,1%), V - 55 (67,9%).
 ,
 : I - 241 (30,6%), II - 156 -
 (20,0%), III - 164 (21,0%), V - 196 (25,1%). -
 3,3% (26) .
 , I, II -
 , V- -
 (p-value 0,001).

6 -

()

		95%	
	2,18	1,2-4,6	0,004**
	2,22	1,3-4,5	0,007**
,	2,98	1,6-4,2	<0,001***
,	2,86	1,5-6,1	0,004**
,	2,15	1,0-4,1	0,034*
	2,25	1,1-4,6	0,004**
	3,25	1,7-6,6	<0,001***
2	2,10	1,0-4,1	0,039*
3	3,26	1,7-6,6	0,006**


* - <0,05; ** - p<0,01, *** - p<0,001.

3,

(11, 7),

Streptococcus agalactiae,

12 ,



Диагональные сегменты формируются совпадениями.

11 – ROC-

7 -

ROC-

()	-	a	b	95%	
.3	,529	,035	,388	,460	,598
Stragalact	,544	,036	,192	,474	,614
12	,650	,036	,000	,579	,721
.	,539	,035	,251	,469	,608

: 3 , Stragalact, gt12 ,

a.

b. : = 0.5.

		B	Exp(B)
1 ^a	.3	,864	,495	3,046	1	,081	2,373
	Stragalact	1,496	,463	10,424	1	,001	4,463
	gt 12	1,754	,265	43,720	1	,000	5,777
	.	,621	,429	2,100	1	,147	1,861
		- 2,827	,159	315,229	1	,000	,059

(1):

$$Z = -2,872 + 0,621 * + 1,754 * + 1,496 * \text{Stragalact} + 0,864 * 3 . \quad (1)$$

,
12 (AUC 0,650, <0,001, 95%,
95% : 0,579-0,721).

,
3 , -
Streptococcus agalactiae, -

.
,
, -
12 ,
(), -
-

.

2- 12 20
 (48,8%), 13 - 4 (9,8%), 14 - 2 (4,9%). -
 12 15 2- (10-
 11 - 8 (19,5%), 8-9 - 3 (7,3%), 6-7 - 3 -
 (7,3%), 4 - 1 (2,4%)).

, p-value

1- 2-

0,156.

22 -
 40 1- (55,0%), 19 41 2- (46,3%),
 =0,513.

Streptococcus

agalactiae 7 (17,5%) 1- 4 (9,8%)
 2- , =0,337.

3- 12 1- (30,0%), -
 16 2- (39,0%), -
 =0,357.

8.

3 -

12

3-

(1985 .).

III 1

2- (2,4%),

V-

8 –


	1- (n=40)	2- (n=41)	
12 , . . (%)	24 (60,0%)	26 (63,4%)	0,156
, . . (%)	22 (55,0%)	19 (46,3%)	0,513
<i>Streptococcus</i> <i>agalactiae</i> , . . (%)	7 (17,5%)	4 (9,8%)	0,337
3- , . . (%)	12 (30,0%)	16 (39,0%)	0,357

* – $p < 0,05$; ** – $p < 0,01$, *** – $p < 0,001$.

1.2.


2- (12,2%) , 3 1- (7,5%) 5 -

,
: 520,0 (380,0; 610,0) 1-
, 510,0 (400,0; 590,0) 2- -
, .
1-
() 2- ,
, 48,0 (40,0; 56,0) 46,0 (41,0;
58,0) . , -
2 .
, 1- , -
5 -
- () 40 (100,0%)
, 3- - 3 (7,5%), 5- - , -
.
, 2- ,
, 5 1- -
41 (100,0%), 3- - 2 (4,9%), 5- ,
1- , ,
.
(>0,05), 10. -
3- -
(1-)
22 (55,0%) 26 (63,4%) 2- .
1-
, 2- -
-
4 (9,8%) 5- (11).



10 –

, -



11 –

,

1.3.

-

,

12 ,

14,8%. 1-

,

2-

(5,0%),

- 10 , 24,4%, =0,015.

,

(=0,015).

2 1-

() (5,0%),


7 2- (17,1%).

() 1 2-

, 2,4%.

2 2-

(4,9%), 12.



12 –

-

,

(2-)

1-

1-

(=0,002).

3-

4 12

(50,0%)

(33,3%),

4-5-

- 6

, 8-

- 2

(16,7%).

,

1-

3-

1

(2,5%),

2-

3-

4

(9,7%),

4-5

4

2

(9,8%),

8-

2- (4,9%).

(8)

(3-, 5-, 8-

2- (14,6%).

2- (4,9%),

(7,3%).

(5,0%) 7 2- (17,1%).

5 2- (12,2%).

3 2- (7,3%).

13.

– 1 1- (2,5%), 2 -

,

8 12

(1 1- (2,5%) 6 -

2- (7,3%).

(1 1- (2,5%) 3 2-

2 1-

(5,0%) 7 2- (17,1%).

2 1- (5,0%),

5 2- (12,2%).

3 2- (7,3%),

13.

,

.

.


.

:

(5,0%), 7 2- (17,1%), « » (2 1-


-

		3	2-	(7,3%).	-
					.
					-
		- 2	1-	(5,0%),	9
2-	(22,0%).				
		4	2-	(9,7%),	
					- 1
					1-
	(2,5%)	7	2-	(17,1%).	



schierichia coli (2 (5,0%) 1- -
 9 2- (22,0%)), 1 1-
 (2,5%) 6 (14,6%) – 2- .
Staphylococcus epidermidis 1 1- (2,5%), -
 , 2 2-
 (4,8%). *Enterococcus faecalis*
 1 2- (2,4%), -
 1 -
 (2,4%). -
 -

14.



(2 1- (5,0%) 6 2- (14,6%)),
 - 1 2- (2,4%).

3-, 5-, 8-

(=0,003)

2

Enterococcus faecalis

50,0%,

15,4%,

S. epidermidis

66,6%

2

()

().

().

(/),

I (), III (),

,

scherichia coli

I (

) 54,5% , II, III (

) – 63,6% 45,5% ,

(/) – 27,2%.

,

27,2%

3- , 2-

45,4% . (/

), (),

,

.coli

.

(/ 1,2 3) –

1 1- (2,5%) 6 2- (14,6%).

III (/ 2 2)

1 1- (2,5%) 4 2- (9,8%).

() 1 2-

(2,4%).

,

,

14,8%

(– -value

<0,001).

1.4.

$-4,2 (3,9; 4,5) \cdot 10^{12}/$ 1- $4,3 (3,9; 4,5) \cdot 10^{12}/$ 2- , -
 $-7,0 (5,2; 8,1) \cdot 10^9/$ $61 (5,0; 7,5) \cdot 10^9/$ 1- 2-
 $-240,0 (218,0; 269,0) \cdot 10^9/$ 1- -
 1- $260,0 (210,0; 290,0) \cdot 10^9/$ 2- ,
 $112,0 (90,0; 122,0) /$, $-12,0 (8,0; 16,0) /$ 1- $10,0$
 $(7,0; 15,0) /$ 2- .
 $68,0 (58,0; 70,0)$ $66,0 (52,0; 74,0)$
 $/$ 1- 2- , $36,0 (29,0;$
 $40,0) /$ 1- $33,0 (28,0; 38,0) /$ 2- .
 1- $82,0 (68,0; 96,0) /$, 2- $-78,0 (69,0;$
 $94,0) /$, -
 1- $6,4 (4,2; 8,9) /$, 2- $-5,8 (4,5; 8,5)$
 $/$, $-5,9 (5,5; 6,1) /$ 1- $5,8 (5,6; 6,0)$
 $/$ 2- . $1-$ -
 $8,6 (6,2; 9,0) /$, 2- $-7,9 (6,0; 8,9) /$,
 $-26,0 (20,0; 30,0)$ $22,0 (19,0; 28,0) /$ -

- 28,0 (22,0; 38,0) 26,0 (20,0; 34,0) / 1- 2- -
 .
 : 94,0 (70,0; 122,0) / 518,0
 (310,0; 762,0) / 1- 102,0 (65,0; 120,0) / 455,0 (328,0;
 789,0) / 2- .
 -
 30,1 (27,2; 33,5) 1-
 29,2 (26,4; 34,2) 2- , - 13,0 (11,5; 14,2)
 1- 12,8 (11,3; 13,4) 2- . -
 0,95 (0,88; 1,05) 1- 0,97
 (0,9; 1,0) 2- . 20,0
 (18,6; 22,3) 1- 21,1 (19,2; 22,6) 2- . -
 1- 3,4 (3,0; 3,6) / , 2- -
 3,3 (2,8; 3,5) / .

1.5.

,
 ,
 .
 : - 1 (TGF- (

9 –

- 1,

,

,

		1- (n=40)	2- (n=41)	
- 1 (TGF- (rs1800470))	(/), . . (%)	12 (30,0%)	14 (34,1%)	0,694
	(/), . . (%)	14 (35,0%)	12 (29,6%)	0,694
<i>eNOS3 (G894T)</i>	(/), . . (%)	8 (20,0%)	6 (14,6%)	0,529
	(G/), . . (%)	10 (25,0%)	14 (34,1%)	0,374
<i>(SERPINE-1, 5G (-675)4G</i>	(4G/4G), . . (%)	9 (22,5%)	11 (26,8%)	0,656
	(5G/4G), . . (%)	16 (40,0%)	20 (48,8%)	0,433

-

,

-

(10).

10 –

- 1,

- 1 (TGF- (rs1800470))		<i>eNOS3</i> (G894T)		(SERPINE-1, 5G (-675)4G	
1	2	3	4	5	6
(/) r _s ; p-value	(/) r _s ; p-value	(/) r _s ; p-value	(G/T) r _s ; p-value	(4G/4G) r _s ; p-value	(5G/4G) r _s ; p-value
0,383; =0,006**	-0,063; =0,576	0,636; <0,001**	-0,084; =0,457	0,083; =0,460	0,047; =0,682
3-					
0,467; <0,001***	-0,205; =0,066	0,461 =0,005**	0,292 =0,025*	0,183 =0,221	-0,171 =0,188
0,660 <0,001***	0,355 =0,010*	0,385 =0,024*	0,137 =0,315	0,314 =0,036*	0,177 =0,174
<i>Streptococcus agalactiae</i>					
0,113 =0,416	0,036 =0,798	0,085 =0,622	-0,157 =0,250	-0,208 =0,166	-0,023 =0,862
0,087 =0,534	-0,035 =0,810	0,046 =0,793	-0,046 =0,743	0,210 =0,062	-0,089 =0,432
(/) r _s ; p-value	(/) r _s ; p-value	(/) r _s ; p-value	(G/T) r _s ; p-value	(4G/4G) r _s ; p-value	(5G/4G) r _s ; p-value
3-					

10					
1	2	3	4	5	6
0,467; <0,001***	-0,205; =0,066	0,461 =0,005**	0,292 =0,025*	0,183 =0,221	-0,171 =0,188
0,660 <0,001***	0,355 =0,010*	0,385 =0,024*	0,137 =0,315	0,314 =0,036*	0,177 =0,174

* – <0,05; ** – p<0,01, *** – p<0,001.

-

-

- 1 (*TGF- (rs1800470)*) (26/81, 32,1%) 8
(8/12, 66,7%) ,

18 (18/69, 26,1%). -

0,383 =0,006, -

- 1

(*TGF- (rs1800470)*) -

26 , 3 -

(3/12, 33,3%), 23 -

(23/69, 33,3%). -0,063

0,576, -

-

- 1 (*TGF- (rs1800470)*) -

.

eNOS3 (G894T) 8 -

(8/12, 66,7%) 6 (6/69, 8,7%), -

0,636, <0,001, -

.

3	(3/12, 25,0%),		25	-
	(25/69, 36,2%).		-0,084,	
	=0,457,		-	
	.		-	
(SERPINE-1, 5G (-675)4G)		4	(4/12, 33,4%),	
16	,		(16/69,	
23,2%).			SERPINE-1, 5G (-	
675)4G			0,083	-
=0,460,			.	-
			(SERPINE-1, 5G (-675)4G)	
	6	(6/12, 50,0%),	30	,
		(30/69, 43,5%).		-
		SERPINE-1, 5G (-675)4G		
		0,047	=0,682,	
		.		
16	3-			
		- 1 (TGF- (rs1800470))	(16/26,	
61,5%),	,		,	
		10	(10/55, 18,2%).	
	0,467		0,001	-
				-
			- 1	3-
			5	,
	.			-
	3-	(5/26, 19,2%)	21	-
		(21/55, 38,2%),		-
-0,205	=0,066		.	

<i>eNOS3 (G894T)</i>		8		3-	
(8/26, 30,8%),	6			(6/55, 10,9%).	-
		0,461	=0,005		-
					-
					<i>eNOS3</i>
(<i>G894T</i>)		18		(18/26, 69,2%),	
10			(18/55, 18,2%).		-
	0,292		=0,025		-
					-
		<i>eNOS3</i>		3-	
(<i>SERPINE-1, 5G (-675)4G</i>)		8		,	
3-	(8/26, 30,8%),		12		-
(12/55,21,8%).				0,183	
=0,221,					-
(<i>SERPINE-1, 5G (-675)4G</i>)		13		3-	
(13/26, 50,0%),	23				
	(23/55, 41,8%).				
20					
- 1 (<i>TGF- (rs1800470)</i>) (20/41, 48,8%),					-
					6
(6/40, 15,0%).				0,660, -value	
0,001,					-
				- 1	-
					-
			15		-
					-

			- 1 (<i>TGF- (rs1800470)</i>) (15/41,	-
36,6%),				
	16		(11/40, 27,5%).	
	0,355,	-value=0,010,		-
	- 1			
.				
<i>eNOS3 (G894T)</i>	10			
	(10/41, 24,4%),	4		
	(4/55, 7,3%).		0,385	
=0,024				-
.				
<i>eNOS3 (G894T)</i>	14			
	(14/41, 34,1%),	14		
	(14/40, 35,0%).			-
0,137	=0,315			-
.				
<i>(SERPINE-1, 5G (-675)4G)</i>	10			-
	(10/41, 24,4%),	10	,	
		(10/40, 25,0%).		-
		<i>SERPINE-1, 5G (-675)4G</i>		-
		0,314		
=0,036,				-
.				
		<i>(SERPINE-1, 5G (-675)4G)</i>		
20				-
	(20/41, 48,8%),	16	,	-
		(16/40, 40,0%).		

18
 (18/70,25,7%).

-0,208 =0,166,

·

(SERPINE-1,

5G (-675)4G) 5 Streptococ-

cus agalactiae (5/11, 45,5%), 31 -

Streptococcus agalactiae

(31/70, 44,3%).

·

,

,

- 1 (TGF- (rs1800470)),

eNOS3 (G894T) -

3-

1.6.

ROC - AUC 0,650, <0,001, 95%, 95% : 0,579-0,721).

3, « » (

Streptococcus agalactiae, -

), 2

12 , 2

(, 3 -

Streptococcus

agalactiae, -

) -

-

-

- 1 (TGF- (rs1800470)),

eNOS3 (G894T),

(SERPINE-1, 5G (-675)4G)

3-


(

« , »,

2021 .),

3-, 5-, 8-

(15).



15 -

1-

4,9%,

2-

24,4%, =0,015.

-

-

.

-

-

-

81 , 9,4%,
()

() -

42 , 4,8%. -

27 (3,1%). 12 -

, -

(1,4%).

3- 39 81

(48,1%), 4-5- - 21 81 (25,9%) -

, 6 - 21 (25,9%).

-

scherichia

coli (18 (22,2%)), 14

. Staphylococcus epidermidis 16 (19,8%), 7

(43,7%). Enterococcus faecalis

17 (21,0%), 9

(52,9%). Enterococcus faecium - 16

(19,8%), 6 -

(37,5%).

(12 81 (14,8%)).

(7 12 (58,3%))

(25,0%), 2 –

(16,7%).

4,0 (3,0; 5,0), – 3,0 (2,0; 3,0).

1,0 (1,0; 2,0)

1

2,0 (2,0; 3,0)

(=0,002 =0,015).

63 (8,1%), (=0,033).

(4,2%), 12 (1,5%).

Escherichia coli –

12 81 (14,8%),

46 (5,9%), <0,001. Enterococcus faecalis

8 (9,8%), 33 (4,2%),

=0,020. Streptococcus agalactiae 9 ,

(11,1%) 22 – (2,8%), <0,001.

Staphilococcus aureus 6

(7,4%) 28 – (3,2%), =0,084. -

Klebsiella 3 (3,7%),

28 (3,6%), =0,744.

, -

, Escherichia coli, Enterococcus

faecalis Streptococcus agalactiae. -

8. -

-

62

(76,5%), 2 , (

377 (48,2%)), <0,001. -

(<0,001), -

(<0,001).

(<0,001).

1

(<0,001).

22 (27,2%), 12 6 7 (8,6%), 6 12
 12 33 (40,7%).

- 181 (23,2%), 6 12 - 122 (15,6%),
 12 - 74 (9,5%).

(<0,001), 6 12 -
 (p=0,006),
 12
 (<0,001).

2,67 (=2,67,
 95% 1,6-4,2).

(=2,83, 95% 1,7-3,9).

(\bar{x} =1,83, 95% 1,1-3,2).

(\bar{x} =3,6, 95% 1,9-6,7).

(\bar{x} =1,55, 95% 1,0-3,0).

95% 1,3-5,2).

(\bar{x} =2,66,

(\bar{x} =1,42, 95% 1,1-2,9).

(\bar{x} =2,83, 95% 1,2-5,5).

(\bar{x} =2,57, 95% 1,3-5,1).

, Escherichia coli (\bar{x} =2,77, 95% 1,2-5,6), Enterococcus faecalis (\bar{x} =2,48, 95% 1,2-4,9) Streptococcus agalactiae (\bar{x} =4,3, 95% 2,1-8,9)

(\bar{x} =3,5, 95% 1,6-7,1).

(\bar{x} =2,49, 95% 1,2-5,0)

(=2,27, 95% 1,1-4,7)

-

.

,

,

-

-

.

6 12

(=1,15, 95% 1,0-2,2).

12

(=4,66, 95% 2,3-9,4).

,

-

,

-

,

.

-

.

-

,

-

,

12

,

,

.

,

(=2,18, 95% 1,2-4,6).

,

,

,

(=2,22, 95% 1,3-4,5),

(=2,15,

95% 1,0-4,1),

2

(=2,10,

95% 1,0-4,1),

3

(=3,26, 95% 1,7-6,6).

-

,

-

(=2,98, 95% 1,6-3,2),

(=2,86, 95% 1,5-6,1).

-

,

(=2,25, 95% 1,1-

4,6)

(=3,25, 95% 1,7-6,6).

12 (AUC 0,650, <0,001, 95%, 95% : 0,579-0,721).

,
 ,
 , 3 ,
 Streptococcus agalactiae,
 .
 ,
 ,
 12 ,
 ,
 .
 .
 -
 .
 ,
 , 12 .
 22 -
 40 1- (55,0%), 19 41 2-
 (46,3%), =0,513.
 Streptococcus
 agalactiae 7 (17,5%) 1- 4 (9,8%)
 2- , =0,337.
 3- 12 1- (30,0%), -
 16 2- (39,0%), -
 =0,357.

3 -

, 12 -

, 3- -

2- (12,2%) 3 1- (7,5%) 5 -

: 520,0 (380,0; 610,0) 1- -

510,0 (400,0; 590,0) 2- -

1- -

() 2- , 48,0 (40,0; 56,0) 46,0 (41,0; 58,0) -

2 -

, 1- , -

5 -

- () 40 (100,0%) -

, 3- - 3 (7,5%), 5- - -

, 2- , -

, 5 1- -

41 (100,0%), 3- - 2 (4,9%), 5- ,

1- , ,

(>0,05).

-

12 ,

14,8%. 1-

(5,0%), 2- , 2

- 10 , 24,4%, =0,015.

,

(=0,015).

2 1-

() (5,0%), 7

2- (17,1%).

() 1 2-

, 2,4%.

2 2-

(4,9%).

,

, (2-)

1-

1-

,

(=0,002).

3- 4 12
 (50,0%), (33,3%), 5- - 6
 , 8- - 2 (16,7%), , -
 1- , 3- 1 -
 (2,5%), 2- 3- -
 4 (9,7%), 4-5 - 4 -
 2 (9,8%), 8- -
 - 1 1- (2,5%), 2 2-
 (4,9%), , (8
) ,
 (3-, 5-, 8-
) .
 8 12
 (1 1- (2,5%) 6 -
 2- (14,6%). 2 -
 , 2- -
 (4,9%), 3 -
 (1 1- (2,5%) 3 2-
 (7,3%). 2 1-
 (5,0%), 5 2- (12,2%).
 3
 2- (7,3%).
 3-, 5-, 8-
 , : -
 (2 1- (5,0%), 7 2- (17,1%)), « »
 3 2-
 (7,3%). -

(22,0%).
 4 2- (9,7%),
 7 2- (17,1%).
 scherichia coli (2 (5,0%) 1-
 9 2-1 (22,0%)), 1 1-
 (2,5%) 6 (14,6%) – 2-
 Staphylococcus epidermidis 1 1- (2,5%),
 (4,8%).
 Enterococcus faecalis
 1 2- (2,4%),
 1
 (2,4%).
 , ,
 , 14,8%
 (– -value
 <0,001).
 , ,
 (3- , 5- , 8-).
 , ,
 (/)
 - 1 (TGF- (rs1800470)) 12 1-

(30,0%), 14 , 2- -
 (34,1%). -
 (/) 14 1- (35,0%), 12 -
 , 2- (29,6%).
 (/) -
 eNOS3 (G894T) ,
 8 1- (20,0%) 6 2-
 (14,6%) .
 (G/) 10 1- (25,0%) 14 2-
 (34,1%) .
 , (4G/4G) 9
 1- (22,5%) 11 (26,8%) 2- -
 .
 (5G/4G) 16 1- (40,0%), 20 2-
 (48,8%).
 ,
 - 1
 (TGF- (rs1800470)), eNOS3 (G894T),
 (SERPINE-1, 5G (-675)4G) -
 -
 , -
 , 3- -
 , -
 -
 .
 -

ROC – AUC 0,650, <0,001, 95%, 95% : 0,579-0,721).

3, « » (

Streptococcus agalactiae,

), 2,

12 , 2

(, 3 -

Streptococcus

agalactiae,

)

- 1 (TGF- (*rs1800470*)),

eNOS3 (G894T),

(*SERPINE-1, 5G (-675)4G*)

3-

(

« , »,-
2021 .), -

, -

.

1-

4,9%,

2-

24,4%, =0,015.

3-, 5-,

8-

,

,

,

,

.

,

-

(

),

.

.

1. -

12 (ROC- 0,650, <0,001,95% : 0,579-0,721),
 Streptococcus agalactiae
 (=4,3, 95% 2,1-8,9),
 (=3,6, 95% 1,9-6,7), 3 (=3,26, 95% 1,7-6,6)
 (=3,25, 95% 1,7-6,6).

2. -

(=0,015).

3. - 1

(TGF- (rs1800470)),
 eNOS3 (G894T) -
 -
 3- (rs=0,467, p<0,001; rs=0,461, =0,005),
 (rs=0,660, p<0,001; rs=0,385,
 =0,024).

4. -

1.	,	12	-
,	2	:	-
		Streptococcus agalactiae,	-
	,	3-	-
			-
	-	.	-
2.	,		-
		12	
		Streptococcus agalactiae,	
	,	3-	-
		,	-
	3-, 5-, 8-	,	
		-	
		.	-
3.			-
		,	-
		-	-
			-
	-	.	

-
- -
-
-
-
-
-
- -
-

1. . . . / . . . ,
. . . , . . . // – 2021.
– 2–3 (72). – . 141–142.
2. – –
, / . . . –
, . . . [.] // . –
. . . . – 2020. – . 8, 1 (27). – . 109–110.
3. /
. . . , . . . , . . . [.] // .
. – 2020. – . 10, 2. – . 149–154.
4. /
. . . , . . . , . . . // . – 2021. – . 23, 1. –
. 6–11.
5. –
/ . . . , . . . //
. – 2021. – . 6, 1. – . 27–31.
6. –
placenta accreta / . . . // – . –
2021. – . 21, 1. – . 84–87.
7. –
/ . . . // . – 2018. – 4 (283). – . 9–11.
8. :
? / . . . , . . . //
. – 2020. – 1. – . 16–22.

9. , . . , -
 / . . , . . , . . // -
 . - 2020. - . 25, 1. - . 5-14.
10. , . . -
 / . . , . . //
 XXI . - 2018. - . 20, 3. - . 32-34.
11. , . . /
 . . , . . , . . // . - 2020. -
 14-1 (107). - . 10-13.
12. - /
 . . , . . , . . [.] // .
 - 2020. - 7. - . 135-142.
13. :
 / . . ,
 . . , . . [.] //
 . - 2020. - . 10, 1. - . 133-149.
14. / . . , . . , . . , . . //
 - . - 2019. - 3-4. - . 28.1.
15. , . .
 2010 2018 " " / . . -
 , . . // . - 2019. - 1. -
 . 64-66.
16. , . . -
 III / . . , . . ,
 . . // . - 2020. - . 27, 2.
 - . 49-58.
17. :
 ? / . . -

- , . . . , . . . [.] // . – 2018. – 6 (359). –
. 60–65.
18. , . . . : -
/ . . . , . . . // . –
2021. – . 28, 4. – . 34–37.
19. , . . . / . . . -
, . . . , . . . // . – 2020. –
2. – . 5–9.
20. , . . .
/ . . . , . . . // -
. – 2020. – . 5, 2. – . 72–78.
21. / . . . ,
. . . , . . . , . . . // . –
2019. – 4 (41). – . 15–20.
22. /
- . . . , . . . , . . . [.] // ,
. – 2021. – . 15, 1. – . 22–31.
23. :
/ . . . , . . . , . . . [.] // -
. – 2021. – 2. – . 77–83.
24. , . . . t. Vejnovic
/ . . . , . . . ,
. . . // . – 2021. – 1. – . 88–93.
25. , . . . " " / . . . ,
. . . , . . . // . – 2021. – 1–3
(71). – . 194–196.

26. , . . . , . . . //
 . – 2021. – . 6, 1. – . 77–83.
27. – () / . . . -
 , . . . [.] // -
 – 2021. – . 8, 1. – . 20–25.
28. / . . . , . . . , . . . -
 // . – 2020. – 2 (36). –
 . 144–146.
29. , -
 COVID-19 /
 . . . , . . . , . . . , . . . //
 . – 2021. – 2. – . 48–54.
30. , . . . , -
 / . . . , . . . //
 Wschodnioeuropejskie Czasopismo Naukowe. – 2021. – 1–1 (65). – . 16–18.
31. , . . . -
 / . . . , . . . , . . . // -
 . – 2020. – 3. – . 130.
32. , . . . -
 / . . . // Global Reproduction. – 2021. – S1. –
 . 12–14.
33. , . . . -
 : hapo / . . . -
 // . – 2021. – 2. – . 13–20.
34. , . . . , . . . [.] // . -
 . – 2020. – . 10, 2. – . 138–148.

35. , . . . / . . . , . . . ,
. . . // . – 2020. – 16. – .58–60.
36. , . . . ,
. . . // 2009–2019 /
. . . // XXVIII –
. – ., 2020. – .28–31.
37. , . . . –
. . . // . – 2021. –
.10, 1. – .49–53.
38. " " (Plasmoliftingtm)
/ . . . , . . . ,
. . . // . – 2017. – 3–2 (24). –
.67–71.
39. , . . .
/ . . . , . . . // .
– 2020. – S4. – .159–161.
40. –
/ . . . ,
. . . , . . . // . . – 2021. – .20, 1.
– .45–49.
41. –
/ . . . , . . . , . . . [.] //
. – 2020. – .27, 1. – .135–145.
42. " "
/ . . . , . . . , . . . [.] //
. – 2021. – 2. – .179–182.

43. / . . . ,
 . . . , . . . // . – 2021. – . 1, 1 (52).
 – . 354–357.

44. , -
 / . . . , . . . -
 , . . . [.] // . – 2020. – 3
 (186). – . 164–168.

45. -
 / . . . , . . . -
 , . . . [.] // . – 2020. –
 . 69, 1. – . 7–16.

46. / . . . , . . . , . . . ,
 . . . // . – 2020. – . 12, 1 (28). – . 17–21.

47. D / . . . , . . . -
 , . . . [.] // .
 . – 2020. – . 17, 1. – . 70–77.

48. / . . . ,
 . . . , . . . // -
 . – 2020. – . 24, 1. – . 64–66.

49. « » / . . . , . . . , . . . -
 [.] // « »: XIV -
 . – ., 2019. – . 58–61.

50. « » -
 (, . 2019) / . . -
 , . . . , . . . // -
 . – 2020. – . 1, 12. – . 52–60.

51. / . . . ,
 . . . [.] // – 2020. – . 3, 1. –
 . 9–15.
52. -
 / . . . , . . . [.] //
 . – 2021. – 1. – . 52–60.
53. , . . .
 / . . . , . . . ,
 . . . // – . – 2020. – . 20, 1. –
 . 5–15.
54. /
 . . . , . . . [.] // .
 – 2020. – 2 (81). – . 72–76.
55. -
 , / . . . , . . . -
 , . . . [.] // – . – 2018. –
 . 18, 5. – . 4–11.
56. :
 / . . . , . . . [.] //
 . – 2019. – . 12, 6. – . 74–80.
57. / . . . -
 , . . . [.] // . –
 2021. – 1. – . 61–69.
58. -
 / . . . ,
 . . . [.] // . – 2020. – . 10,
 1. – . 19–23.
59. 1 .
 / . . . // . – 2020. – 47. – . 579–582.

60. -
 / . . . , . . . , . . . ,
 . . . // - 2020. - . 10,
 1. - . 15-21.
61. -
 / . . . , . . . , . . . , . . . -
 // - 2019. - . 7,
 S. - . 93-100.
62. -
 / . . . , . . . , . . . [.] // -
 . - 2021. - 4. - . 150-156.
63. -
 / . . . , . . . , . . . // -
 . - 2020. - 18 (102). - . 33-37.
64. -
 / . . . , . . . -
 , . . . // . - 2020. - 2 (30). -
 . 672-675.
65. -
 / . . . , . . . , . . . -
 // , . - 2020. - . 19. -
 2. - . 96-103.
66. -
 / . . . // -
 . - 2021. - . 2, 1. - . 39-41.
67. -
 / . . . -
 , . . . , . . . , . . . // .
 - 2021. - 2. - . 27-31.

68. / . . . , . . . ,
 . . . [. . .] // . - 2021. - . 11, 1. - . 45-51
69. / . . . , . . . , . . . //
 . - 2021. - 1. - . 159-172.
70. , . . . / . . . // . -
 2021. - 2. - . 61-68.
71. / . . . , . . . , . . . , . . . //
 . - 2018. - 5 (160). - . 12-16.
72. , . . . II
 / . . . , . . . , . . . // -
 - . - 2021. - . 21, 2. - . 56-61.
73. :
 / . . . , . . . , . . . ,
 . . . // . - 2020. - . 101, 3. -
 . 418-425.
74. / . . . , . . . , . . . [. . .] //
 . - 2017. - 2 (69). - . 22-28.
75. , . . . / . . . , . . . //
 . - 2021. - . 1, 21. - . 33-35.
76. , . . . / . . . , . . . , . . . -
 // . - 2020. - 2 (72). - . 115-117.

77. / . . ,
 . . [.] // -
 - 2020. - . 20, 2. - . 41-46.

78. -
 / . . , . . , . . ,
 . . // . - 2020. - . 24, 1. -
 . 67-69.

79. Abdominal Incision Selection for Cesarean Delivery of Women with Class III Obesity / A.L. Sutton, L.B. Sanders, A. Subramaniam [et al.] // *Am. J. Perinatol.* - 2016. - Vol. 33, 6. - P. 547-51.

80. Accouchement du prématuré / A. Eckman, N. Mottet, R. Ramanah, D. Riethmuller // *J. Gynecol. Obstet. Biol. Reprod. (Paris)*. - 2015. - Vol. 44, 8. - P. 781-6.

81. Adverse infant outcomes associated with caesarean section delivery in India / T. Gondwe, K. Betha, G.N. Kusneniwar [et al.] // *Int. Health.* - 2020. - Vol. 12, 5. - P. 411-416.

82. Adverse pregnancy outcomes related to preterm cesarean delivery / T. Kino, Y. Yamamoto, Y. Saigusa [et al.] // *Eur. J. Obstet. Gynecol. Reprod. Biol.* - 2019. - Vol. 234. - P. 89-91.

83. Al-Zalabani, A.H. Is cesarean section delivery associated with autism spectrum disorder? / A.H. Al-Zalabani, A.H. Al-Jabree, Z.A. Zeidan // *Neurosciences (Riyadh)*. - 2019. - Vol. 24, (1). - P. 11-15.

84. Balatero, J.S. Barriers to Skin-to-Skin Contact after Cesarean Birth / J.S. Balatero, A.F. Spilker, S.G. McNiesh // *MCN Am. J. Matern. Child Nurs.* - 2019. - Vol. 44, 3. - P. 137-143.

85. Bonner, S. Complex maternal congenital anomalies - a rare presentation and delivery through a supra-umbilical abdominal incision / S. Bonner, Y. Mohammed // *J. Obstet. Gynaecol.* - 2018. - Vol. 38, 6. - P. 874-875.

86. Cesarean delivery and prematurity / R. Simões, R.C. Cavalli, W.M. Bernardo [et al.] // *Rev. Assoc. Med. Bras.* - 2015. - Vol. 61, 6. - P. 489-94.

87. Cesarean section by maternal request / R. Câmara, M. Burlá, J. Ferrari [et al.] // *Rev. Col. Bras. Cir.* – 2016. – Vol. 43, 4. – P. 301–10.

88. Cetisli, N.E. Maternal attachment and breastfeeding behaviors according to type of delivery in the immediate postpartum period / N.E. Cetisli, G. Arkan, E.D. Top // *Rev. Assoc. Med. Bras.* – 2018. – Vol. 64, 2. – P. 164–169.

89. Chankhunaphas, W. Effect of elastic abdominal binder on pain and functional recovery after caesarean delivery: a randomised controlled trial / W. Chankhunaphas, K. Charoenkwan // *J. Obstet. Gynaecol.* – 2020. – Vol. 40, 4. – P. 473–478.

90. Ci cie cesarskie a zaburzenia zwi zane z narz dem wzroku / I. Karska–Basta, M. Tarasiewicz, A. Kubicka–Trz ska [et al.] // *Ginekol. Pol.* – 2016. – Vol. 87, 3. – P. 217–21.

91. Dickinson, J.E. Caesarean delivery: truths and consequences / J.E. Dickinson // *Aust. N. Z. J. Obstet. Gynaecol.* – 2014. – Vol. 54, 4. – P. 295–7.

92. Effect of delivery method on sexual dysfunction / B.K. Saydam, M. Demireloz Akyuz, N. Sogukpinar, E. Ceber Turfan [et al.] // *J. Matern. Fetal Neonatal Med.* – 2019. – Vol. 32, 4. – P. 568–572.

93. Effects of Cesarean Section and Vaginal Delivery on Abdominal Muscles and Fasciae / C. Fan, D. Guidolin, S. Ragazzo [et al.] // *Medicina (Kaunas).* – 2020. – Vol. 56, 6. – P. 260.

94. Emergency caesarean section / M. Gosset, A. Ilenko, J. Bouyou, B. Renevier // *J. Visc. Surg.* – 2017. – Vol. 154, 1. – P. 47–50.

95. Evaluation of cesarean delivery rates at three university hospital labor units using the Robson classification system / J. Zahumensky, P. Psenkova, B. Nemethova [et al.] // *Int. J. Gynaecol. Obstet.* – 2019. – Vol. 146, 1. – P. 118–125.

96. Exploring the skin-to-skin contact experience during cesarean section / A.C. Frederick, N.H. Busen, J.C. Engebretson [et al.] // *J. Am. Assoc. Nurse Pract.* – 2016. – Vol. 28, 1. – P. 31–8.

97. Extra-abdominal removal of placenta during cesarean section: a prospective randomized controlled trial of a novel technique / B. Kaya, O. Guralp, K. Daglar [et al.] // *J. Perinat. Med.* – 2016. – Vol. 44, 5. – P. 557–65.

98. Fahmy, W.M. Association between maternal death and cesarean section in Latin America: A systematic literature review / W.M. Fahmy, C.A. Crispim, S. Cliffe // *Midwifery.* – 2018. – Vol. 59. – P. 88–93.

99. Fasciite nécrosante de la paroi abdominale post-césarienne / S. Barant, D. Radbata, D. Oberweis [et al.] // *Rev. Med. Brux.* – 2016. – Vol. 37, 3. – P. 178–182.

100. Feeding Behaviors and Breastfeeding Outcomes After Cesarean Section / F. Zhang, J. Cheng, S. Yan [et al.] // *Breastfeed Med.* – 2019. – Vol. 14, 5. – P. 325–333.

101. Female sexual outcomes in primiparous women after vaginal delivery and cesarean section / F.N. Amiri, S. Omidvar, A. Bakhtiari, M. Hajiahmadi // *Afr. Health Sci.* – 2017. – Vol. 17, 3. – P. 623–631.

102. Guidelines for Antenatal and Preoperative care in Cesarean Delivery: Enhanced Recovery After Surgery Society Recommendations (Part 1) / R.D. Wilson, A.B. Caughey, S.L. Wood [et al.] // *Am. J. Obstet. Gynecol.* – 2018. – Vol. 219, 6. – P. 523.

103. Guidelines for intraoperative care in cesarean delivery: Enhanced Recovery After Surgery Society Recommendations (Part 2) / A.B. Caughey, S.L. Wood, G.A. Macones [et al.] // *Am. J. Obstet. Gynecol.* – 2018. – Vol. 219, 6. – P. 533–544.

104. Hofer, J.E. Microparticle Release During Normal Cesarean Delivery / J.E. Hofer, B.M. Scavone // *Anesth. Analg.* – 2018. – Vol. 126, 3. – P. 925–927.

105. Influences of Cesarean Delivery on Breastfeeding Practices and Duration: A Prospective Cohort Study / C. Chen, Y. Yan, X. Gao [et al.] // *J. Hum. Lact.* – 2018. – Vol. 34, 3. – P. 526–534.

106. Maskey, S. Prevalence of Cesarean Section and Its Indications in A Tertiary Care Hospital / S. Maskey, M. Bajracharya, S. Bhandari // *JNMA J. Nepal Med. Assoc.* – 2019. – 57 (216). – P. 70–73.

107. Mode of Delivery Does Not Affect the Risk of Inflammatory Bowel Disease / C. Frias Gomes, N. Narula, B. Morão [et al.] // *Dig. Dis. Sci.* – 2021. – Vol. 66, 2. – P. 398–407.

108. Nitric oxide: what's new to NO? / K. Ghimire, H.M. Altmann, A.C. Straub, J.S. Isenberg // *Am. J. Physiol. Cell Physiol.* – 2017. – Vol. 312, 3. – P. C254-C262.

109. Operative Technique and Experience of One Referral Center With Vaginal Cesarean Delivery / S. Delplanque, M. Le Lous, H. Isly [et al.] // *Obstet. Gynecol.* – 2020. – Vol. 135, 2. – P. 409–414.

110. PAI-1 4G/4G Genotype Is Associated with Recurrent Implantation Failure: a Systematic Review and Meta-analysis / H. Zeng, D. He, L. Hu [et al.] // *Reprod. Sci.* – 2021. – Vol. 28, 11. – P. 3051-3060.

111. Pereira, T.R.C. Implications of pain in functional activities in immediate postpartum period according to the mode of delivery and parity: an observational study / T.R.C. Pereira, F.G. Souza, A.C.S. Belezza // *Braz. J. Phys. Ther.* – 2017. – Vol. 21, 1. – P. 37–43.

112. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review / Q. Zhang, Y. Jin, X. Li [et al.] // *Vasa.* – 2020. – Vol. 49, 2. – P. 141-146.

113. Rayhan, S.K. Does delivery in private hospitals contribute largely to Caesarean Section births? A path analysis using generalised structural equation modelling / S.K. Rayhan // *PLoS One.* – 2020. – Vol. 15, 10. – P. e0239649.

114. Rise, E. Is there any association between abdominal strength training before and during pregnancy and delivery outcome? The Norwegian Mother and Child Cohort Study / E. Rise, K. Bø, W. Nystad // *Braz. J. Phys. Ther.* – 2019. – Vol. 23, 2. – P. 108–115.

115. Sax, M.R. Persistent Abdominal Pain 2 Years After Cesarean Delivery / M.R. Sax, J.L. Whiteside // *Obstet. Gynecol.* – 2019. – Vol. 134, 1. – P. 102–105.
116. Sharma, S. Cesarean vs Vaginal Delivery : An Institutional Experience / S. Sharma, I. Dhakal // *JNMA J. Nepal Med. Assoc.* – 2018. – 56 (209). – P. 535–539.
117. Shea, S.K. Prevention of Cesarean Delivery Surgical Site Infections / S.K. Shea, D.E. Soper // *Obstet. Gynecol. Surv.* – 2019. – Vol. 74, 2. – P. 99–110.
118. Sonographic evaluation for intra-abdominal hemorrhage after cesarean delivery / C. Hoppenot, J. Tankou, S. Stair, D.R. Gossett // *J. Clin. Ultrasound.* – 2016. – Vol. 44, 4. – P. 240–4.
119. Staples vs. Sutures After Cesarean Delivery / K. Fayssoux, R. Mahmood, J. Grindle, S. Nass // *Am. Fam. Physician.* – 2018. – Vol. 98, 1. – P. 50.
120. Study of the state of stress-implementing systems in abdominal delivery depending on anesthetic techniques / M.A. Georgiyants, O.V. Votska, N.P. Seredenko [et al.] // *Wiad Lek.* – 2020. – Vol. 73, 11. – P. 2378–2385.
121. TGF-1 suppresses CCL3/4 expression through the ERK signaling pathway and inhibits intervertebral disc degeneration and inflammation-related pain in a rat model / J. Zhang, Z. Li, F. Chen [et al.] // *Exp. Mol. Med.* – 2017. – Vol. 49, 9. – P. e379.
122. TGF-1-transfected tendon stem cells promote tendon fibrosis / H. B. Yu, J. Xiong, H. Z. Zhang [et al.] // *J. Orthop. Surg. Res.* – 2022. – Vol. 17, 1. – P. 358.
123. The Case for Standardizing Cesarean Delivery Technique: Seeing the Forest for the Trees / J.D. Dahlke, H. Mendez-Figueroa, L. Maggio [et al.] // *Obstet. Gynecol.* – 2020. – Vol. 136, 5. – P. 972–980.
124. Tillett, J. Gentle Cesarean Delivery / J. Tillett // *J. Perinat. Neonatal Nurs.* – 2015. – Vol. 29, 4. – P. 267–9.
125. Väärasmäki, M. Pregnancy and delivery after a cesarean section / M. Väärasmäki, T. Raudaskoski // *Duodecim.* – 2017. – Vol. 133, 4. – P. 345–52.